SITE DIRECTED PROTEIN ANALYSIS WITH NOVEL AMINO ACIDS

使用新型氨基酸进行定点蛋白质分析

• 批准号: 2615375
• 负责人: VLADIMIR A KARGINOV
• 金额: $ 9.91万
• 依托单位: ANNOVIS, INC.
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-01-01 至 1998-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2615375
• 关键词: aminoacid; aminoacyl tRNA; genetic translation; peptide chemical synthesis; protein engineering; site directed mutagenesis; synthetic protein

Bearsden Bio, Inc. is developing novel research kits for sale to the scientific community through its Cruachem division and is developing a technology based on regulating protein expression at the RNA level. The overall goal of this SBIR program is the development and commercialization of a method for the preparation of quantities of proteins containing unnatural amino acids at single, predetermined sites. For Phase I, we plan to demonstrate the feasibility of establishing an efficient, robust method for the elaboration of such proteins. This is to be done by realizing two specific aims, namely 1. Demonstration of the applicability of a novel protecting group to a broad cross of aminoacylated tRNAs. 2. Realization of an increase in the yield of proteins prepared by in vitro translation, where introduction of an unnatural amino acid involves suppression of a nonsense codon with a misacylated suppression tRNA. Completion of this progrartant modifications for understanding protein function. PROPOSED COMMERCIAL APPLICATION: The final development of a robust, efficient misacylated synthesis system will benefit Bearsden in two ways: as a novel kit for sale to the research community and as an enabling technology for use in drug discovery. The latter will represent an important advance in ArnaX Integrated Rational Drug Discovery program as it enables a more thorough understanding of RNA Binding Proteins and other pharmacologically important proteins.

Bearsden Bio，Inc.正在开发新的研究套件，销售给 科学界通过其Cruachem部门，并正在开发一个 基于在RNA水平上调节蛋白质表达的技术。 的 该SBIR计划的总体目标是开发和 商业化的方法，用于制备大量的 在单个预定位置含有非天然氨基酸的蛋白质 网站. 在第一阶段，我们计划展示以下方法的可行性： 建立一个有效的，强大的方法来制定这样的 proteins. 这将通过实现两个具体目标来实现，即1。 证明新的保护基对一种化合物的适用性。 氨酰化tRNA的广泛交叉。 2. 实现增加 通过体外翻译制备的蛋白质的产率，其中 引入非天然氨基酸涉及抑制 无义密码子与错酰化抑制tRNA。 完成本 前体修饰以了解蛋白质功能。 拟定商业应用： 一个强大的，有效的错酰化合成的最终发展 系统将有利于比尔斯登在两个方面：作为一个新的套件销售的 作为一种使能技术， 的发现 后者将代表Arnax的一个重要进步 整合的合理药物发现计划，因为它可以更彻底地 了解RNA结合蛋白和其他蛋白质 重要蛋白质